<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880382</url>
  </required_header>
  <id_info>
    <org_study_id>IB 2019-07</org_study_id>
    <secondary_id>2020-005562-34</secondary_id>
    <nct_id>NCT04880382</nct_id>
  </id_info>
  <brief_title>Integrative Analysis of the Tumor Microenvironment and Optimization of the Immunotherapy Duration in Non-small Cell Lung Cancer Patients.</brief_title>
  <acronym>OPTIMUNE-LUNG</acronym>
  <official_title>Integrative Analysis of the Tumor Microenvironment and Optimization of the Immunotherapy Duration in Non-small Cell Lung Cancer Patients. OPTIMUNE-LUNG Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-comparative multicentric randomized study to assess long-term benefit of PD-1 inhibition&#xD;
      in NSCLC patients who experienced a response between 6 and 12 months after initiation of ICI&#xD;
      (immune checkpoint inhibitor PD1/PDL-1 blockade therapy)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two-arm, non-comparative, prospective, multicentric, randomized study for early&#xD;
      discontinuation of immune checkpoint inhibitor PD1/PDL-1 blockade therapy in non-small cell&#xD;
      lung cancer patients who achieved objective response between 6 and 12 months after treatment&#xD;
      onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized phase II study in which eligible patients will be randomized (1:1) according to two therapeutic strategies</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the long-term benefit of PD-1 inhibition in NSCLC patients who experienced a response between 6 and 12 months after initiation of ICI</measure>
    <time_frame>12 months</time_frame>
    <description>Long-term benefit will be assessed in terms of progression-free rate (PFR) at 12 months after randomization, for each therapeutic strategy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of secondary resistance in NSCLC patients who experienced a response to PD1/PDL-1 inhibition</measure>
    <time_frame>12 months</time_frame>
    <description>The rate of patients who develop progression (as per RECIST v1.1) due to secondary resistance after obtaining a response to PD1/PDL-1 inhibition, independently for each therapeutic strategy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response independently for each therapeutic strategy</measure>
    <time_frame>Throughout the treatment period, an expected average of 12 months</time_frame>
    <description>Duration of response (DoR) defined as the time interval between the first response (complete or partial response as per RECIST v1.1) to the time of the first documentation of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year progression-free survival, independently for each therapeutic strategy</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival (PFS) defined as the time interval between the date of randomization and the date of progression or death, whichever occurs first. Progression will be determined according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year progression-free survival, independently for each therapeutic strategy</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival (PFS) defined as the time interval between the date of randomization and the date of progression or death, whichever occurs first. Progression will be determined according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival, independently for each therapeutic strategy</measure>
    <time_frame>1 year</time_frame>
    <description>Overall Survival (OS) defined as the time interval between the date of randomization and the date of death (of any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival, independently for each therapeutic strategy</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival (OS) defined as the time interval between the date of randomization and the date of death (of any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile, independently for each therapeutic strategy: Common Terminology Criteria for Adverse Events version 5</measure>
    <time_frame>Throughout the treatment and follow-up period, an expected average of 12 months</time_frame>
    <description>Toxicity graded using the Common Terminology Criteria for Adverse Events version 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To describe retreatment for arm B-patients and subsequent systemic therapies for arm A-patients</measure>
    <time_frame>Throughout the treatment and follow-up period, an expected average of 12 months</time_frame>
    <description>Number of patients retreated by ICI will be described in Arm B. Similarly, for arm A-patients, number of patients treated by subsequent systemic therapy will be described</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor immune cells levels</measure>
    <time_frame>At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months)</time_frame>
    <description>Levels of immune cells in tumor will be measured by immunohistochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cytokines levels</measure>
    <time_frame>At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months)</time_frame>
    <description>Levels of cytokines in blood will be measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lymphocytes levels</measure>
    <time_frame>At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months)</time_frame>
    <description>Levels of lymphocytes in blood will be measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood kynurenine levels</measure>
    <time_frame>At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months)</time_frame>
    <description>Levels of kynurenine in blood will be measured by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Arm A: treatment by ICI will be continued</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After achieving objective response between 6 and 12 months after treatment onset, for these patients ICI treament will continue as per market authorization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm B: treatment by ICI will be discontinued</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After achieving objective response between 6 and 12 months after treatment onset, for these patients first-line or second line regimen should be discontinued. Patients will be followed as per standard management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICI treatment discontinuation</intervention_name>
    <description>After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter</description>
    <arm_group_label>Experimental Arm B: treatment by ICI will be discontinued</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICI treatment continuation</intervention_name>
    <description>After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity</description>
    <arm_group_label>Standard Arm A: treatment by ICI will be continued</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed non-small cell lung carcinoma (squamous or&#xD;
             non squamous).&#xD;
&#xD;
          2. Locally advanced/unresectable or metastatic disease.&#xD;
&#xD;
          3. For non-squamous histology, tumor with no oncogenic addiction: no activating EGFR&#xD;
             mutation, no ALK or ROS1 rearrangement,&#xD;
&#xD;
          4. Treatment with ICI (immune checkpoint inhibitor PD1/PDL-1 blockade therapy):&#xD;
&#xD;
               1. in first or second-line treatment as per market authorization. For patients in&#xD;
                  first line, ICI alone or ICI + chemotherapy,&#xD;
&#xD;
               2. start of ICI treatment 6 to 12 months (+/- 2 weeks) before registration.&#xD;
&#xD;
          5. At least one measurable lesion according to the RECIST v1.1 criteria before ICI&#xD;
             treatment onset and confirmed by centralized review (lesion in previously irradiated&#xD;
             filed can be considered as measurable if progressive at inclusion according to RECIST&#xD;
             v1.1). At least one site of disease must be uni-dimensionally ≥ 10 mm.&#xD;
&#xD;
          6. Patient with objective response according to RECIST v1.1 criteria at 6 months or more&#xD;
             and less than 12 months after ICI treatment onset. Response must be confirmed by&#xD;
             centralized review&#xD;
&#xD;
          7. At least one lesion that can be biopsied for research purpose.&#xD;
&#xD;
          8. Age ≥ 18.&#xD;
&#xD;
          9. Performance status &lt; 2.&#xD;
&#xD;
         10. Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to registration.&#xD;
&#xD;
         11. Patient with a social security in compliance with the French law (Loi Jardé).&#xD;
&#xD;
         12. Patient must be willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests and other study procedures.&#xD;
&#xD;
         13. Voluntarily signed and dated written informed consent prior to any study specific&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female who is pregnant or breast-feeding.&#xD;
&#xD;
          2. Concomitant disease or condition that could interfere with the conduct of the study,&#xD;
             or that would, in the opinion of the investigator, pose an unacceptable risk to the&#xD;
             subject in this study.&#xD;
&#xD;
          3. Hypersensitivity to one of the active substances or to one of the excipients&#xD;
&#xD;
          4. Any contraindication to pursue ICI treatment as per investigator judgement.&#xD;
&#xD;
          5. Previous enrolment in the present study.&#xD;
&#xD;
          6. Individual deprived of liberty or placed under legal guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie COUSIN, MD</last_name>
    <phone>5.56.33.33.33</phone>
    <phone_ext>+33</phone_ext>
    <email>s.cousin@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone MATHOULIN-PELISSIER, MD, PhD</last_name>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie COUSIN, MD</last_name>
      <email>s.cousin@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie COUSIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune checkpoint inhibition</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>treatment duration</keyword>
  <keyword>long-term benefit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

